Acuitas Therapeutics To Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

Vancouver, B.C. – Acuitas Therapeutics, the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, today announced its participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference. Tom Madden, CEO of Acuitas Therapeutics will deliver a featured presentation and connect with industry leaders throughout the event.

Bloom Burton & Co. Healthcare Investor Conference
● Presentation Date: April 21st at 10:30am
● Location: Toronto, ON, Canada

To schedule a meeting with the Acuitas team during the conference, please visit: www.acuitastx.com/contact

About Acuitas Therapeutics

Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.    

Acuitas’ clinically validated LNP technology has had a profound global impact – most notably enabling the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. The technology also enables ONPATTRO® by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas’ LNP technology has delivered other groundbreaking firsts: the first in-human proof of concept for genome base editing and the first personalized CRISPR therapy.   

Today, Acuitas is advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic and in vivo CAR T-cell therapies, epigenetic medicines to modulate gene expression without altering DNA, multivalent vaccines for infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines.    

For more information, visit www.acuitastx.com. 

-END-